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This book provides a timely overview of this important anti-
cancer drug. An introductory chapter includes useful
synopses of each of the following chapters. The next four
chapters deal with aspects of the chemistry, pharmacology,
metabolism and clinical use of tamoxifen and its actions on
the oestrogen receptor. Many of these individual topics have
been extensively reviewed elsewhere, but it is useful to have
them all brought together in one volume. Where appropriate,
the author has often prefaced discussion ofeach topic with a
brief general introduction to the biological background. For
example the chapter on Metabolism and Toxicology (Chapter
3) begins with a useful summary of the CYP nomenclature
used for classifying cytochrome P450 enzymes. The author
covers most of the major areas of interest and current
controversy. The references at the end ofeach chapter though
not comprehensive, are sufficient to allow the reader to gain
entry into the literature of a particular field. These are
commendably up to date, some predating publication of the
book by only a month or two. An example (p. 27) is a
reference to a recent hypothesis that proposes how tamoxifen
produces liver DNA adducts.
More than half the book is concerned with apparently
oestrogen-independent actions oftamoxifen, the later chapters
reflecting the author's personal research interests. This is
nevertheless welcome, as it provides a different emphasis from
most reviews on this drug. The first of these later chapters
describes how tamoxifen modulates certain oncogenes and
growth factors. Again there is a simple introduction to
oncogenes and the relevant growth factor accompanied by
clear diagrams illustrating their functions. This chapter also
includes a discussion of mechanisms of resistance. Inhibition
ofenzymes is the main subject ofthe following chapter. These
include enzymes in cell signalling pathways, such as protein
kinase C (PKC), and calmodulin-dependent enzymes. There
follows a discussion of the role of the anti-oestrogen binding
site (AEBS). A minor criticism here is that the discussion of
the structural requirements for ligand binding refers to the
work ofVan den Koedijk et al. on the rat AEBS. Their later,
potentially more relevant, study on the human AEBS shows a
different structure-activity relationship.
A discussion of the effect of tamoxifen and 4-hydroxy-
tamoxifen on cholesterol synthesis forms a useful prelude to a
following chapter on the antioxidant action of tamoxifen.
The first 17 pages of this chapter are a general description of
cell membrane structure and function. However, this lengthy
introduction is a necessary background to the discussion that
follows. In this, the basis thesis is that tamoxifen protects the
cell membrane against lipid peroxidation by decreasing
membrane fluidity. A variety of beneficial consequences
proposed to result from this action include inhibition of
metastasis, reversal of the multidrug resistance phenotype
and cardio-protection.
The penultimate chapter describes the actions oftamoxifen
on the yeast Saccharomyces cerevisiae. Analogies with
mammalian control mechanisms justify the use of the yeast
model. These include similarities in Ras- and PKC-mediated
pathways, and in functions of calmodulin. Moreover, the
model may help to validate tamoxifen as a candidate drug for
use in fungal infections caused by Candida.
The brief concluding chapter compares tamoxifen with
some of its major competitors, to which the book also refers
earlier. This last chapter also mentions an approach to the
design of a compound, structurally similar to tamoxifen,
which could treat prostatic cancer.
In attempting to cover all aspects of tamoxifen's actions,
the treatment of some topics has been at times uncritical of
interpretations found in the literature. Occasionally this has
led to factual errors and contradictory statements. For
example, it is probably not true that ovarian cancer cells can
metabolise tamoxifen to 4-hydroxytamoxifen (p. 22). Induc-
tion of TGF f (p. 63) is a more likely basis for the anti-
carcinogenic effect oftamoxifen than suppression ofhydrogen
peroxide production by neutrophils (p. 147). 4-Hydroxyta-
moxifen is a potent inhibitor ofthe growth ofMCF-7 cells (p.
22). This is incompatible with the later statement (p. 165) that
it does not inhibit yeast cell growth 'probably because it is a
polar compound and is unable to enter the yeast cell'. Of the
tamoxifen analogues toremifene and droloxifen (p. 27), only
the latter has a shorter half-life than the parent drug.
Moreover, this is not necessarily advantageous as the
literature claims (p. 197). Compared with tamoxifen, it will
lead to a lower exposure of the drug for a given dose.
However, these are minor criticisms. Generally, the broad
coverage is beneficial, serving to stimulate though this suggests
fruitful avenues for further research.
This useful and highly readable volume should be on the
bookshelves foreveryone engagingin research on tamoxifen. It
also contains much to interest the general reader. Many
research areas covered as fast moving and facts and
interpretations quickly date. I hope, therefore, that the author
may in due course find time to produce a revised version.
M Jarman
Drug and Hormol Resstanc in Breat Cancer: Celabr and
Molecudr Mecdia_m
Edited by RB Dickson and ME Lippman, Ellis Horwood:
Hemel Hempstead, 1995, 440 pp. £112.50. ISBN 0-13-224858-
1
This is generally an excellent book giving a thorough
treatment to an area of major clinical importance. The
editors themselves are well known as excellent researchers in
this field but they did not in fact contribute substantially to
the writing. They have, however, been able to attract a first
class array of writers to cover the subject comprehensively.
The book is divided into four parts with parts 2 and 3
making up about two-thirds of the book:
1. Clinical Resistance
2. Antihormonal Drugs: mechanism of action and resis-
tance
3. Chemotherapeutic Drugs: mechanisms of resistance
4. Chemohormonal Interactions.
In Part 1 Tripathy and Henderson contribute an excellent
chapter discussing the general approach for deriving
mechanistic data from clinical trials while emphasising the
danger of simple intrapolation and extrapolation. A chapter
by Gusterson on the changing role of the pathologist in
predicting tumour behaviour and response to treatment
might not be expected in this book but nonetheless contains
worthwhile data.
Throughout the clinical resistance section and Part 2 there
is substantial repetition. For example, the data on the
importance of c-erb-2 as an indicative marker of response/
resistance to adjuvant chemotherapy must be mentioned in
two-thirds of the chapters. It is likely, however, that the